Published in Transl Gastroenterol Hepatol on September 21, 2017
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int (2014) 2.26
Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer (2008) 2.24
Biologics in organ transplantation. Transpl Int (2012) 2.06
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant (2007) 1.69
Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. Sci Transl Med (2014) 1.42
Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant (2004) 1.40
Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol (2006) 1.40
Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology (2010) 1.39
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant (2005) 1.33
An appraisal of tolerance in liver transplantation. Am J Transplant (2006) 1.32
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22
Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant (2003) 1.21
Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl (2012) 1.18
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2012) 1.16
Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc (1993) 1.08
Tolerance: is it worth the risk? Transplantation (2005) 1.03
The mTOR pathway in hepatic malignancies. Hepatology (2013) 1.02
EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol (2015) 1.02
Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation (2007) 1.01
Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibody. Transplantation (1990) 1.01
Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 1.01
Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol (2013) 1.00
Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc (1997) 0.92
FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation (2008) 0.92
The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol (2008) 0.89
The essential roles of parenchymal tissues and passenger leukocytes in the tolerance induced by liver grafting in rats. Nat Med (1995) 0.87
From immunosuppression to tolerance. J Hepatol (2015) 0.87
Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl Immunol (2004) 0.84
Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology (2017) 0.82
Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc (2005) 0.82
Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. Ann Surg (2014) 0.81
Long-term follow-up of 23 operational tolerant liver transplant recipients. Transplantation (2010) 0.80
Tolerance induction: hematopoietic chimerism. Curr Opin Organ Transplant (2013) 0.79
Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol (2016) 0.79
Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database. PLoS One (2016) 0.78
Transplantable liver production plan: "Yamaton"--liver project, Japan. Organogenesis (2013) 0.78
Recurrent Hepatocellular Carcinoma After Liver Transplantation: Analysis of Risk Factors. Transplant Proc (2016) 0.78
The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up. Transpl Int (2012) 0.77
The use of novel diagnostics to individualize immunosuppression following transplantation. Transpl Int (2015) 0.77
Can immunosuppression be stopped after liver transplantation? Lancet Gastroenterol Hepatol (2017) 0.77
Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy (2017) 0.76
Recellularization of organs: what is the future for solid organ transplantation? Curr Opin Organ Transplant (2014) 0.76
Prognostic Value of Pre-transplantation Serum Alpha-Fetoprotein Levels in Hepatocellular Carcinoma Recurrence. Transplant Proc (2016) 0.76